Cases
Johnson & Johnson (JNJ)
Securities Class Action
Overview
Overview
- Date:
- 12/14/2018
- Company Name:
- Johnson & Johnson
- Stock Symbol:
- JNJ
- Status:
- Closed/Complete
NEW YORK, December 14, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against Johnson & Johnson (NYSE: JNJ). Our investigation concerns whether Johnson & Johnson has violated the federal securities laws and/or engaged in other unlawful business practices.
On December 2, 2018, Reuters issued a report headlined “Johnson & Johnson knew for decades that asbestos lurked in its Baby Powder.” Reuters reported that internal company documents reveal that scientific tests of the talc it used to manufacture baby powder and other products from as early as 1957 showed asbestos contaminants. As reported by Reuters, the information concerning the asbestos contaminated talc was slow to come to light because “[m]any were shielded from public view by court orders that allowed J&J to turn over thousands of documents it designated as confidential.”
On this news, Johnson & Johnson’s share price fell by more than 10%, closing at $133.00 per share on December 14, 2018.
If you purchased or otherwise acquired Johnson & Johnson shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On December 2, 2018, Reuters issued a report headlined “Johnson & Johnson knew for decades that asbestos lurked in its Baby Powder.” Reuters reported that internal company documents reveal that scientific tests of the talc it used to manufacture baby powder and other products from as early as 1957 showed asbestos contaminants. As reported by Reuters, the information concerning the asbestos contaminated talc was slow to come to light because “[m]any were shielded from public view by court orders that allowed J&J to turn over thousands of documents it designated as confidential.”
On this news, Johnson & Johnson’s share price fell by more than 10%, closing at $133.00 per share on December 14, 2018.
If you purchased or otherwise acquired Johnson & Johnson shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.